drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Patient T cells are gene-modified ex vivo to express a CD19-targeting CAR and infused to deplete CD19+ B-lineage cells (naive and memory B cells, plasmablasts), aiming to reduce autoantibody production and B cell–driven inflammation in SLE.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered ex vivo to express a CD19-targeting chimeric antigen receptor; upon infusion they recognize and kill CD19-positive B-lineage cells (naive and memory B cells, plasmablasts) via cytotoxic mechanisms, reducing autoantibody production and B cell–driven inflammation in SLE.
drug_name
RD06-04
nct_id_drug_ref
NCT06310811